Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (8630)	2/4/1999 4:16:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George it might be all in the handle. Maybe Wohanka just doesn't do it for some people.<g> Maybe try CurleyWohankito!

To: aknahow who wrote (8630)	2/4/1999 10:49:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

George, the CORR example was something like (not exact numbers, not available to me right now) a decrease from an incidence of 9.5% to 8%. The absolute difference is 1.5%, but 1.5% is 16% of 9.5%, then one get a 16% decrease in the incidence of heart infarcts (not bad). Heart infarcts are a grave and severe complication of Angina (the Integrilin indication) and this is prevention of attacks, for prevention a much lower number is accepted. Plus, is cheaper than the other drugs available, it actually comes from rattles snakes (not snake oil, but protein). But, for your 50% confidence level then you will need to proof that the effect is not due to chance 1 out of 2 times (just pure flip of a coin!!) Well, to do this you will need tens of thousands of patients to proof your effectiveness. Nobody will pay for that study. ICOS IC14 phase II for sepsis will start soon. They are the next in the race (probably a good future combination with BPI/E5/lpb).